TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8957369

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 704

Group type: EXPERIMENTAL
Intervention: Pump-prime-only aprotinin
Number of subjects: 704

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study: 1416125

Group type: EXPERIMENTAL
Intervention: 0.7% end‐tidal isoflurane in O2
Number of subjects: 20

Group type: COMPARATOR
Intervention: 70% N2O in O2
Number of subjects: 20
Study: 2989349

Group type: EXPERIMENTAL
Intervention: Enalapril (5 to 10 mg orally)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Enalapril (long-term treatment)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (long-term treatment)
Number of subjects: 23
Study: 30025837

Group type: EXPERIMENTAL
Intervention: Push‐Ortho‐Thumb‐Brace‐CMC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Custom‐made orthosis
Number of subjects: 16
Study: 30257655

Group type: EXPERIMENTAL
Intervention: Individualized Prevention Practitioner (PP) visit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (wait-list control)
Number of subjects: 0
Study: 27216013

Group type: EXPERIMENTAL
Intervention: Palaeolithic diet
Number of subjects: 13

Group type: COMPARATOR
Intervention: Diabetes diet
Number of subjects: 13
Study: 25453518

Group type: EXPERIMENTAL
Intervention: co-supplemented hemp seed and evening primrose oils with advised Hot-nature diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: co-supplemented oils
Number of subjects: 100

Group type: COMPARATOR
Intervention: olive oil
Number of subjects: 100
Study: 22370434

Group type: EXPERIMENTAL
Intervention: better weight (BW) cognitive behavioral intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: better weight-better sleep (BWBS) intervention
Number of subjects: 49
Study: 20974575

Group type: EXPERIMENTAL
Intervention: Raltegravir 800 mg once daily
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Raltegravir twice daily for 3 months then once daily
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Prior NRTI resistance
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: No prior NRTI resistance
Number of subjects: 222
Study: 18580206

Group type: EXPERIMENTAL
Intervention: Peritoneal drain
Number of subjects: 69

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 69
Study: 17017631

Group type: EXPERIMENTAL
Intervention: Liquid whitening gel (5.9% hydrogen peroxide, twice a day for 15 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sodium chlorite‐based whitening gel applied in a tray system (10 minutes twice a day)
Number of subjects: 60
Study: 14617500

Group type: EXPERIMENTAL
Intervention: Pager reminder system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring only
Number of subjects: 0
Study: 10594426

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study: 8922488

Group type: EXPERIMENTAL
Intervention: Piracetam (n = 48)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (n = 39)
Number of subjects: 87
Study: 1405245

Group type: EXPERIMENTAL
Intervention: Nitroglycerin‐retard (n = 20; Group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Corovas (n = 20; Group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (n = 10; Group 3)
Number of subjects: 50
Study: 2860739

Group type: EXPERIMENTAL
Intervention: STA‐MCA bypass in addition to medical therapy (daily aspirin and aggressive hypertension control)
Number of subjects: 1377

Group type: COMPARATOR
Intervention: Medical treatment alone (daily aspirin and aggressive hypertension control)
Number of subjects: 1377
Study: 31836434

Group type: EXPERIMENTAL
Intervention: Palbociclib + letrozole
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo + letrozole
Number of subjects: 666
Study: 31563038

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control session (resting and reading magazines)
Number of subjects: 30
Study: 28625036

Group type: EXPERIMENTAL
Intervention: Sago worm inclusive diet (100 g per day for 45 days)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group eating a usual diet without sago worms
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sago worm inclusive diet
Number of subjects: 23
Study: 26309676

Group type: EXPERIMENTAL
Intervention: Deep-breathing training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Oxygen inhalation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of deep-breathing exercises and oxygen inhalation
Number of subjects: 42
Study: 23648640

Group type: EXPERIMENTAL
Intervention: Disulfiram (0, 250, 375, or 500 mg/d)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 41
Study: 22215944

Group type: EXPERIMENTAL
Intervention: Lidocaine swab
Number of subjects: 80

Group type: COMPARATOR
Intervention: Spray
Number of subjects: 80
Study: 17852792

Group type: EXPERIMENTAL
Intervention: FMD/NMD during normoxia (21% O2, 79% N2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FMDHyp/NMD during inhaling hypoxic gas (12.5% O2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FMDO2/NMD during 100% O2 supplementation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 20
Study: 16492207

Group type: EXPERIMENTAL
Intervention: Pioglitazone (initial dose 15 mg/day, increased to 30 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Voglibose (initial dose 0.6 mg/day, increased to 0.9 mg/day)
Number of subjects: 30
Study: 15611421

Group type: EXPERIMENTAL
Intervention: Contact Allergen Replacement Database group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional therapy group
Number of subjects: 29
Study: 11515703

Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 708

Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 708
Study: 9294378

Group type: EXPERIMENTAL
Intervention: Medication alone for 14 months
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Psychosocial treatment alone for 14 months
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: Combination of medication and psychosocial treatment for 14 months
Number of subjects: 576

Group type: COMPARATOR
Intervention: Community comparison (routine community care)
Number of subjects: 576
Study: 8403175

Group type: EXPERIMENTAL
Intervention: Regularly dosed oral morphine (20 mg every four hours)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Oral placebo (equivalent dose every four hours)
Number of subjects: 47
Study: 3956052

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 42
Study: 31472099

Group type: EXPERIMENTAL
Intervention: Emollient treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diaper dermatitis group
Number of subjects: 0
Study: 30033655

Group type: EXPERIMENTAL
Intervention: Who's Challenging Who? training
Number of subjects: 236

Group type: COMPARATOR
Intervention: Delayed training (control group)
Number of subjects: 236
Study: 27716604

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg, oral, twice a day for 4 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (matching placebo, oral, twice a day for 4 weeks)
Number of subjects: 50
Study: 22639952

Group type: EXPERIMENTAL
Intervention: Visual assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Planimetry assessment
Number of subjects: 0
Study: 22555328

Group type: EXPERIMENTAL
Intervention: Cefaclor, 50 mg/kg/day, administered twice daily for five days
Number of subjects: 435

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate, 40 mg/kg/day administered twice daily for 10 days
Number of subjects: 435
Study: 20380787

Group type: EXPERIMENTAL
Intervention: Subjects with leg pain
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal and pain control subjects
Number of subjects: 120
Study: 18039994

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 610

Group type: COMPARATOR
Intervention: Anxiety assessment
Number of subjects: 610
Study: 16105921

Group type: COMPARATOR
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Open Repair (OR)
Number of subjects: 40
Study: 12378667

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.1 mg kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.15 mg kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.22 mg kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.3 mg kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.29 mg kg‐1 (ED95)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 10529324

Group type: EXPERIMENTAL
Intervention: Streptokinase therapy with r-hirudin or heparin
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: No ST segment elevation resolution (<30%) at 90 min
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: No ST segment elevation resolution (<30%) at 180 min
Number of subjects: 1208
Study: 7775684

Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no TENS)
Number of subjects: 20
Study: 2270358

Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 50 mg.kg‐1.h‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline infusion (placebo)
Number of subjects: 10
Study: 531232

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (200 mg x 3)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Indomethacin (25 mg x 3)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (0.5 g x 3)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31045851

Group type: EXPERIMENTAL
Intervention: HeadCoach online manager training
Number of subjects: 210

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 210
Study: 29944435

Group type: EXPERIMENTAL
Intervention: Electronic symptom reporting
Number of subjects: 21
Study: 27643994

Group type: EXPERIMENTAL
Intervention: Experience Sampling Method (ESM) assessments focusing on symptoms of psychosis
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Strategic focus on 'paranoia' as the most central symptom
Number of subjects: 1
Study: 24052453

Group type: EXPERIMENTAL
Intervention: Alcohol Care Management (ACM)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Standard treatment in specialty outpatient addiction treatment program
Number of subjects: 163
Study: 22703421

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 μg
Number of subjects: 652

Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 iu
Number of subjects: 652
Study: 19224679

Group type: EXPERIMENTAL
Intervention: ACTS infusion intervention
Number of subjects: 404

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 404
Study: 17805075

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (30 microg of ethinyl estradiol and 0.3 mg of norgestrel) for 2 years
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 150
Study: 15356032

Group type: EXPERIMENTAL
Intervention: Essential amino acids and carbohydrates supplementation (16.5 g essential amino acids and 30 g carbohydrates at 1100, 1600, and 2100 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group received a nutritionally mixed meal every 5 hours (0830, 1330, and 1830 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Essential amino acids and carbohydrates supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12174005

Group type: EXPERIMENTAL
Intervention: Ivermectin 200 micro g/kg orally
Number of subjects: 110

Group type: COMPARATOR
Intervention: 10% benzyl benzoate topically
Number of subjects: 110
Study: 10442367

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2 IV infusion on day 1) and UFT (300-600 mg/day orally) plus oral calcium folinate (90 mg/day in three divided doses for 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UFT (300-600 mg/day orally) plus oral calcium folinate (90 mg/day in three divided doses for 14 days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2 IV infusion on day 1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UFT (600 mg/day orally)
Number of subjects: 20
Study: 7822661

Group type: EXPERIMENTAL
Intervention: 100 micrograms of budesonide per day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 200 micrograms of budesonide per day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 400 micrograms of budesonide per day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Budesonide doses
Number of subjects: 19
Study: 2218423

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 270

Group type: COMPARATOR
Intervention: Beta-lactams (including imipenem/cilastatin, ticarcillin/clavulanic acid, cefpirome)
Number of subjects: 270
Study: 708024

Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg doxycycline (or 4 mg/kg in patients less than 15 years old)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Multiple doses of doxycycline, 500 mg over 4 days (or 10 mg/kg in patients less than 15 years old)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg doxycycline (or 4 mg/kg in children)
Number of subjects: 65
Study: 30418098

Group type: EXPERIMENTAL
Intervention: Early intensive systolic blood pressure lowering treatment
Number of subjects: 0
Study: 28052471

Group type: EXPERIMENTAL
Intervention: Oral health education computer game
Number of subjects: 109

Group type: COMPARATOR
Intervention: One-to-one education
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Both methods of education
Number of subjects: 109
Study: 25676207

Group type: EXPERIMENTAL
Intervention: Imagining positive outcomes of non‐drinking during a social occasion
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Imagining strategies required for non‐drinking during a social occasion
Number of subjects: 211

Group type: COMPARATOR
Intervention: Combined condition (imagining both positive outcomes and required strategies)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control condition (completing a drinks diary task)
Number of subjects: 211
Study: 23416718

Group type: EXPERIMENTAL
Intervention: Remifentanil (2 ng.ml‐1 target)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.2 ng.ml‐1 target)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both opioids (Remifentanil and Sufentanil)
Number of subjects: 40
Study: 20811168

Group type: COMPARATOR
Intervention: Brown envelope
Number of subjects: 2803

Group type: COMPARATOR
Intervention: White envelope
Number of subjects: 2803

Group type: COMPARATOR
Intervention: Brown envelopes (meta-analysis)
Number of subjects: 2803

Group type: COMPARATOR
Intervention: White envelopes (meta-analysis)
Number of subjects: 2803

Group type: COMPARATOR
Intervention: Brown envelopes (after excluding one study)
Number of subjects: 2803
Study: 19373635

Group type: EXPERIMENTAL
Intervention: Peak flow meter (PFM) action plan (n = 31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Symptom-based action plan (n = 32)
Number of subjects: 63
Study: 16923247

Group type: EXPERIMENTAL
Intervention: Allopurinol (an inhibitor of xanthine oxidase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exercise (exhaustive physical exercise)
Number of subjects: 0
Study: 15606222

Group type: EXPERIMENTAL
Intervention: Intravenous ceftriaxone 1g and intravenous azithromycin 500 mg daily
Number of subjects: 212

Group type: COMPARATOR
Intervention: Intravenous levofloxacin 500 mg daily
Number of subjects: 212
Study: 14752875

Group type: EXPERIMENTAL
Intervention: Physical therapy intervention (five sessions of physical therapy and an individualized home exercise program)
Number of subjects: 28
Study: 10424316

Group type: EXPERIMENTAL
Intervention: Captopril 12.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7481947

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (EBF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breastfeeding with supplementary foods (BF+SF)
Number of subjects: 0
Study: 2283608

Group type: EXPERIMENTAL
Intervention: Electrosurgical needle incision
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional scalpel incision
Number of subjects: 0
Study: 6786730

Group type: EXPERIMENTAL
Intervention: Protective environment with prophylactic oral nonabsorbable antibiotics
Number of subjects: 95

Group type: COMPARATOR
Intervention: Open ward care
Number of subjects: 95
Study: 30886898

Group type: EXPERIMENTAL
Intervention: Budesonide combined with noninvasive mechanical ventilation (10 days treatment)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Budesonide combined with noninvasive mechanical ventilation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Noninvasive mechanical ventilation
Number of subjects: 82
Study: 28146658

Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg daily for 24 months)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study: 25957224

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin therapy (loading dose of 300 mg of clopidogrel on day 1, followed by 75 mg of clopidogrel per day for 90 days, plus 75 mg of aspirin per day for the first 21 days)
Number of subjects: 5170

Group type: COMPARATOR
Intervention: Aspirin alone (75 mg/d for 90 days)
Number of subjects: 5170

Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin therapy
Number of subjects: 5170

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 5170
Study: 24077452

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab-plus-pemetrexed
Number of subjects: 0
Study: 21419306

Group type: EXPERIMENTAL
Intervention: Continuous ultrasonic irrigation (CUI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Side‐vented needle irrigation (SNI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both techniques (CUI and SNI)
Number of subjects: 20
Study: 19272750

Group type: EXPERIMENTAL
Intervention: Positive interpretational Cognitive Bias Modification (CBM‐I)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 34
Study: 17251510

Group type: EXPERIMENTAL
Intervention: Probiotic cheese (50 g daily)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Control cheese (50 g daily)
Number of subjects: 276
Study: 15823764

Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg/ibuprofen 400 mg
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498
Study: 11525072

Group type: EXPERIMENTAL
Intervention: Physical exercise program for eight months, with an intensity of 60% to 80% of heart rate reserve, consisting of three weekly sessions of 60 minutes each.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group maintained normal activity.
Number of subjects: 63
Study: 9489588

Group type: EXPERIMENTAL
Intervention: u-hFSH
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: r-hFSH
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: r-hFSH (i.v.)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: u-hFSH (i.v.)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: r-hFSH (i.m. and s.c.)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: u-hFSH (i.m. and s.c.)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: r-hFSH and u-hFSH
Number of subjects: 134
Study: 7836206

Group type: EXPERIMENTAL
Intervention: Handgrip training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 17
Study: 31677386

Group type: EXPERIMENTAL
Intervention: BCG-Denmark
Number of subjects: 2851

Group type: COMPARATOR
Intervention: BCG-Russia
Number of subjects: 2851

Group type: EXPERIMENTAL
Intervention: BCG-Japan
Number of subjects: 2851
Study: 29198593

Group type: EXPERIMENTAL
Intervention: asymmetric CTA membranes
Number of subjects: 16
Study: 26440690

Group type: EXPERIMENTAL
Intervention: Alexis O cesarean delivery retractor
Number of subjects: 301

Group type: COMPARATOR
Intervention: Conventional handheld retractors
Number of subjects: 301
Study: 24052416

Group type: EXPERIMENTAL
Intervention: MICA-TKA (Minimally Invasive and Computer-Assisted Total Knee Arthroplasty)
Number of subjects: 87

Group type: COMPARATOR
Intervention: C-TKA (Conventional Total Knee Arthroplasty)
Number of subjects: 87
Study: 22634964

Group type: EXPERIMENTAL
Intervention: Acute bicarbonate (0.3 g/kg BM)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Chronic bicarbonate (0.5 g/kg BM daily for 3 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Calcium carbonate placebo
Number of subjects: 7
Study: 20022032

Group type: EXPERIMENTAL
Intervention: Adaptive spaced education system
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nonadaptive spaced education system
Number of subjects: 62
Study: 19246266

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy (MMH)
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Ligasure hemorrhoidectomy
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Hemorrhoidal artery ligation procedure
Number of subjects: 1276

Group type: COMPARATOR
Intervention: Conventional excisional surgery
Number of subjects: 1276